Next Biosimilars Hurdle: Winning Over Physicians
This article was originally published in The Pink Sheet Daily
Executive Summary
Data necessary for regulatory approval may not be sufficient for prescribers, Pfizer’s Sophie Opdyke tells Pharmaceutical Strategy Conference.